H&R2019 Lecture Series: Sharad Patel on Portal Vein Pulsatility and Hyponatremia!

 

 

So here was a late-breaker talk at H&R2019. Portal vein pulsatility and hyponatremia by a nephrologist – intensivist. Love it. Sharad, a really great guy, also recently published a case report on this topic.

There is a lot of stuff on venous congestion in the woodwork, some of which we are involved in, but also some springing up from different places, and this is really exciting, because POCUS gives you a non-invasive tool to assess and differentiate pathological degrees of congestion that really nothing else can with as much breadth, and as part of a comprehensive exam.

Venous POCUS is worth learning, and keep your eye on this space for how it evolves as a clinical tool. Our VEXUS classification will soon have some real substance behind it.

For those who want more H&R2019, the Essentials can be found here!

And here’s Sharad!

RV Doppler: Resistance vs. Back Pressure. Jon-Emile Kenny & Korbin Haycock! #FOAMed #FOAMer #FOAMcc #POCUS

So I’m still trying to digest the RVOT Doppler physiology and working my hand at generating the best views and Doppler angles I can (See previous post on RVOT Doppler here). Not sure yet how this will fit in to my clinical practice but I think it’s worth shining a light into this murky pseudo-science of resuscitation. These guys are helping define its potential use… Naturally, this is bleeding-edge stuff. Use it to try to understand what’s going on with your patient’s physiology, don’t use this on board exams! My comments in bold.

Now for the big guns…

 

Jon-Emile Kenny (@heart_lung), pulmccm.org, heart_lung.org

Hey Guys – great discussion as always!
One thing that I find confusing on this topic, and is helpful – i think – when scrutinizing the literature, is the difference between ‘impedance’ and ‘resistance.’ Elevated vascular ‘resistance’ is often used too broadly; for example, true/pure WHO II pulmonary venous hypertension [say from acute left atrial pressure hypertension, but before chronic, compensatory pulmonary arterial changes] is actually typified by a *decrease* in resistance, but an increase in *impedance.* To make things more confusing, acute left atrial hypertension will often display a high “resistance” mathematically … even though, the true resistance can be low. What am i saying? if you imagine an acute increase in the left atrial pressure, the pulmonary venous beds and pulmonary vascular beds “recruit and dilate” backwards [why we see cephalization on the CXR] typically from the bottom to the top of the lungs up the hydrostatic gradient. Recruitment and dilation actually *increases* the cross-sectional radius/area of the vascular beds — a true decrease in resistance [Poiseuille what?]! But, as these vascular beds are engorged, they reach that infamous, hockey-stick-shaped compliance curve point [go leafs go!], where the vessels become really stiff … that is, the compliance falls such that each ejection the RV throws into this dilated circulation, the pressure rises dramatically [especially the systolic pulmonary pressure] …

This I think is a key concept to understand and keep in mind when analyzing the venous system. The physical characteristics are more akin to a floppy plastic bag or balloon, with little rise in pressure until a certain point, then a sharp one – Jon’s “hockey stick.”  It was Jon who made me realize that, with exposure to chronically elevated right atrial pressures, one could have a very big IVC (say 25-30mm, but in fact a low CVP, whereas in normal IVCs exposed to normal CVPs, that sharp rise in pressure probably occurs somewhere around 20mm. Hence, the + value we use in the PAP calculation using TR Vmax for the RAP may be very inaccurate in chronically elevated PAP… Food for thought.

Thus, the calculated pressure gradient rises and and the calculated resistance falls, but what has actually happened is that compliance has fallen, not “resistance”. More broadly, the term “impedance” is composed of compliance, resistance and something called the characteristic impedance [the Windkessels!]. Typically what abnormal RV Doppler shows you is that *impedance* has risen. At the end, you are often still left with the why? Impedance can rise when “true resistance “falls, but compliance also falls [as above] – yet the calculated RVSP/regurgitant jet will also rise. The linked papers are fantastic, but they both excluded patients with left heart disease, so you can be more confident that the RVOT abnormalities seen are related to true ‘pre-capillary’ problems. I’d be willing to bet [and if there’s data, i’d be interested to read it] that patients with pure WHO II pulmonary venous hypertension have very similar abnormalities on the right side. The key means to distinguish – as Korbin talks about – is really looking at the left heart [E/e’] and clinical context to get a better sense of what’s going on.

What would also be interesting would be to look at acutely “decompensated” true left heart disease in volume overload and correlated with RVOT morphology and great vein Doppler velocimetry. My guess is that as you decongest the pulmonary veins [increase their compliance] that the RVOT envelope “pulsatility” goes away [the RV ejection envelope appears more rounded] as does the venous pulsatility in the great veins and intra-renal veins! It’s all about energy transfer … moving away from excessive potential energy trapped in distensible structures [i.e. congestion] to kinetic energy [normal, forward blood flow]

Jon.

 

Korbin (@khaycock2)

Thanks for the reply Jon-Emile, as usual you bring an incredible amount of intelligent well thought out points.

As you mentioned, afterload is much better described in terms of the 3-element Windkessel model as resistance is only one component of said model (the other factors being vascular compliance and characteristic impedance). Please correct me if I’m wrong, but I believe that the most practical and easiest way to non-invasively determine arterial load is to calculate the Ea (formula: (SBP*0.9)/SV). This would include all of the factors that determine afterloading conditions instead of simply using resistance as it is only one of those factors.

Clinically speaking, I think it is important to address why afterloading conditions are abnormal when we come across undifferentiated pulmonary HTN in the acute setting. Practically in my mind, this is simply finding if the pHTN is due to post-capillary “back pressure” from elevated left atrial pressures or due to elevated pre-capillary pulmonary vascular resistance (or could be some combination of both of course). Both of these conditions can cause elevated pulmonary artery pressures, as you have pointed out, and there are a few other contributors to the afterload as well that we are ignoring (or else we’d blissfully nerd out all day and forget to take care of the patients).

I agree with this concept. This is what may direct me to use pulmonary vasodilators, whether inhaled or even the choice of milrinone or vasopressin (not a vasodilator per se but a non-pulmonary vasoconstrictor). If all the pulmonary hypertension is post-capillary, there would be little or no benefit. This important decision point is what prompts me to look into this whole right-sided Doppler thing… Let’s see what else Korbin has to add! 

So how can find out the cause(s) of the elevated PAP? Is it resistance or back pressure from the left atrium? This is essentially the topic of the post. Because PVR=(mPAP-LAP)/CO, it has been suggested that the TR gradient can be a surrogate for the mPAP-LAP and RVOT VTI be a surrogate for CO. Thus if the ratio is high, we can assume that a significant component of the pHTN is due to resistance in addition to or to the exclusion of the contribution of LAP. You have rightly questioned and very well explained why you wonder if these are valid assumptions that translate to the finding the clinical causes of pHTN.

You pointed out that the cited papers in the post excluded patients with LV failure, thus bringing into question if the TR/VTI ratio methods and their permutations are actually detecting PVR as the primary etiology of the pHTN or are corrupted by elevations in LAP. Here are 3 papers that included a significant number of patients with pHTN and elevated PCWPs as measured by RHC that show that the TR/VTI methods do seem to work to detect PVR elevations themselves even if the LAP are high:

1) Am J Cardiol. 2013 September 15; 112(6): 873–882. doi:10.1016/j.amjcard.2013.05.016.
2) J Am Soc Echocardiogr 2013;26:1170-7.
3) J Am Coll Cardiol 2003;41:1021–7.

Somewhere in my files I have a study that shows that the mid systolic notch is fairly specific for high PVR and independent of LAP as well. but apologies, I’d have to look for it.

As I might have mentioned in the audio portion of the post (I can’t remember), there is a second method to flesh out PVR from LAP causes of pHTN. First, you need to find a good estimation of the LAP. ECHO has multiple ways of various accuracies to get a number. The formulas are listed above. I don’t believe any of them are validated in acutely sick patients though. Once you have a LAP number, turn your attention to the pulmonary valve regurgitant jet which will almost always be there if there’s pHTN. The wave form is sort of down-sloping trapezoidal lasting through diastole. The velocity at end-diastole can be squared, multiplied by 4, then added to the RAP to give you the end-diastolic PAP. This is normally < 6 mmHg higher than the LAP pressure measurement, if it is a bit more higher, there likely is increased PVR. This is the same principle used in a RHC, where the inflation of the balloon stops flow and therefore eliminates resistance so that the PCWP can be measured and differentiated from the dPAP. The problem with this method is that it doesn’t work as well as the TR/VTI methods

I really enjoyed your thoughts about how Doppler waveform patterns may be affected once compliance limits have been reached, and I’m sure there is something to this that is real as well no doubt! I thought it might be helpful to provide you with the additional studies that included the patients with high LAP, and do a bit of re-explaining/restating your points to anyone new to this stuff.

Thanks again Jon!

Jon replies:

Hey Korbin – thanks for the references – I’ll dig into them. My main concern is that the mPAP-LAP will disproportionately rise (mostly because the sPAP disproportionately rises) when the left atrial pressure is high … that is when it’s actually not a “resistance” problem but rather a back pressure problem, the mathematical resistance is high. As you mention, this is why there’s a push to move away from “PVR” with RHC and more towards the dPAP-PCWP gradient which should be less than 6 mmHg. I made a cartoon describing this in an old post (https://pulmccm.org/critical-care-review/icu-physiology-1000-words-folly-pulmonary-vascular-resistance/). Thanks for these references, I’ll read them and see if they make sense from the framework I’ve adopted – which is entirely stolen from this great article

Naeije, R., et al., The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J, 2013. 41(1): p. 217-23.

Maybe Phil should do a point-counterpoint podcast where Rory comes in at the end and shakes his head because nothing really matters in the end.

“Nihilism rules…”

Jon

Korbin:

Thanks Jon, I would like to see what you think. Thanks back at you for the reference you mentioned in your reply. And you’re hilarious!

Jon replies:

I had a read of the references that you provided, thank you. I think my concerns still apply, however. My main concern is what is being used as the gold standard for ‘pulmonary vascular resistance.’ An elevated calculated pulmonary vascular resistance (e.g. in WU) doesn’t actually tell you where the pathology is. the assumption is that an elevated calculated pulmonary vascular resistance is caused by a high pre-capillary resistance in the pulmonary circulation, but this isn’t necessarily true. as i showed in that post that i linked to (https://pulmccm.org/critical-care-review/icu-physiology-1000-words-folly-pulmonary-vascular-resistance/) … if one were to acutely cross-clamp the descending aorta, below the diaphragm, the calculated pulmonary vascular resistance would rise, even though the pathology is totally outside of the thorax!! i have no doubt that the TRV / RVOT-VTI would also rise in that very same patient with the cross-clamped descending aorta such that the good correlation between the calculated ‘pulmonary vascular resistance’ and the TRV / RVOT-VTI is maintained – but the pathology is in the abdomen – not the pulmonary vascular tree! So many exclamation marks; but i’m not yelling. In a hypothetical patient with a cross-clamped descending aorta, one might be tricked into giving a pulmonary vasodilator — but that would be the absolute wrong thing to do, even though the calculated pulmonary vascular resistance is high. The treatment is to afterload reduce the struggling LV (remove the cross clamp) — which would then lower the calculated “pulmonary” vascular resistance and the TRV / RVOT-VTI.

the problem in reasoning lies in what happens with the left atrial pressure rises (as would happen if one acutely cross-clamped the descending aorta). it is assumed that as the LAP rises that the mPAP – LAP gradient stays the same or rises in proportion. but what happens when the LAP rises is that the mPAP rises disproportionately because of pulmonary vascular engorgement/stiffening (in fact, the pulmonary vascular resistance has fallen because of recruitment and dilation of the pulmonary tree). what *does* rise in proportion is the dPAP – LAP gradient [should stay below 7 mmHg]. i strongly suspect that the ability of the TTE to detect/calculate the dPAP – LAP gradient is not yet refined enough because there is a lot of supposition and inference when making dPAP and LAP measurements with pulsed wave Doppler.

alas, with either an elevated TRV / RVOT-VTI (or calculated pulmonary vascular resistance from a RHC), one still doesn’t know if it’s purely a left-sided problem (e.g. purely elevated LV afterload) – which could seriously alter management. to know that, i think that a full interrogation of the left heart and pulmonary veins must be done before knowing exactly what an elevated TRV / RVOT-VTI specifically identifies. in addition to that vascular resistance post above, i dug into some more of this in a discussion on the SIOVAC trial a while back (https://pulmccm.org/randomized-controlled-trials/choose-wisely-avoid-sildenafil-pulmonary-hypertension-corrected-left-heart-valvular-disease-siovac-trial/) – which, in my opinion, should never have passed ethics.

Jon

So this is really fascinating stuff. I must admit both Korbin and Jon make excellent points, and for now am not sure if and how to use RV Doppler in clinical decision-making, but until then will be sure to polish up these skills so that they are ready for prime time, and use them in observation of physiology in my shock patients. We’ll see what conclusions I draw.

cheers

 

Philippe

H&R2019 Lecture Series: Rory Spiegel on Acid Base! #FOAMed, #FOAMer

So here is a really solid lecture by Rory (@EMnerd) on his approach to acid base disorders. Definitely worth a listen, and probably the way I will go about teaching it from now on!

 

His slides can be found here.

For those who want more H&R2019, click here. Category 1 CME likely to come in the next weeks!

Exploring the Pulmonary Vasculature with Korbin Haycock: RVOT Doppler. #FOAMed, #FOAMcc, #POCUS

So some recent twitter discussions, particularly involving my friend Korbin (@khaycock2) and Lars (@LMSaxhaug) – whom I am trying to get on the podcast soon – were really fascinating in regards to RV and pulmonary hypertension assessment. So time to dig into this a little.
The basic POCUS RV assessment is RV:LV ratio and TAPSE, along with RV free wall thickness (should be below 5mm) and the D sign in parasternal SAX. This is a solid start to screen for significant RV dysfunction.
The next level should be to measure PAP using TR Vmax, in order to assess the degree of pulmonary hypertension. Thats pretty much where I’ve been at for the last few years and wasn’t sure there was really a lot more that was necessary from an acute care standpoint where your immediate questions are fluids/pressors/inotropes and some inhalational pulmonary dilators. I wasn’t convinced I needed more.
But of course Korbin and Lars are on another level, and started to talk about doing RVOT doppler and looking at TR Vmax to RVOT VTI ratios to estimate pulmonary vascular resistance. Is there any difference there? Is my PAP not enough? Well, turns out there may be some useful information there, so I will let Korbin do the talking, and my apologies for my dumb questions during this discussion!
So I will be toying with RVOT doppler and trying to see if this is something that warrants a place in acute care management. I suspect it may be something that may tip towards earlier inhaled vasodilator therapy, or else make not using them a more confident choice. I do like the waveform analysis. I think we generally overlook a lot of good info by focusing on numbers over morphology!
So far, images using the PS SAX view have been quite good:
Additionally, RVOT notching could be suggestive of an acute PE – makes sense (study link here!)
Here are a couple of excellent references:
So thanks to Korbin and Lars for forcing me to up my doppler game some more!
cheers
Philippe
Formula Fun:
Tricuspid regurgitation pressure gradient for sPAP:
sPAP=4*(TRvelocity^2) + RAP or
sPAP=TRpg +RAP
mPAP=(sPAP)*0.61 + 1.9
Acceleration time equations for sPAP and mPAP:
sPAPlog= -0.004(AT) + 2.1
mPAP=90 – (0.62*AT)
Pulmonary Regurgitation pressure gradient:
mPAP=4*(Peak initial velocity^2) +RAP
dPAP=4*(End velocity^2) + RAP
dPAP-PCWP should be about <6mmHg or else PVR is likely, see PCWP equations below
PVR equation to screen for increased PVR, or if PVR < 3 WU:
PVR=10*(TRvelocity/RVOT VTI) + 0.16. TR velocity is in m/sec, if <2 WU, no increased PVR.  This equation is accurate up to 3 WU
PVR equations for increased PVR > 3 WU.  These equations less accurate if PVR < 3 WU:
PVR=5.19*(TRvelocity^2) – 0.4, or more simplified: 5 * (TRvelocity^2). Note that the 5 * (TRvelocity^2 is almost sPAP equation (4 * TRvelocity^2)=sPAP
PVR=sPAP/RVOT VTI if no RVOT notch present
PVR=(sPAP/RVOT VTI) + 3 if RVOT notch is present
PCWP equations (for detection of group 2 pHTN to elevated sPAP), as you know, this is a whole other area, and gets a quite a bit more complicated, but to summarize:
PCWP likely elevated if E/e’>15, unlikely if E/e'<8
In NSR, PCWP=1.24 * (E/lateral e’) + 1.9
In ST, PCWP=1.5 * (E/lateral e’) + 1.5
In atrial fibrillation averaged over 5 beats, PCWP=0.8 * (E/lateral e’) +6
Using color M-mode and propagation velocity: PCWP=5.27 * (E/Vp) + 4.6

H&R2019 Lecture Series: Salvage the Airway! by Laura Duggan. #FOAMed, #FOAMcc, #FOAMer

So here is an awesome lecture by Laura Duggan (@drlauraduggan) on early airway management.

Enjoy!

 

 

 

…and for more lectures full of clinical pearls, (including Laura Duggan’s Workshop!) the Essentials of H&R2019 On Demand are available here:

H&R2019 The Hospitalist & The Resuscitationist: The Essentials On Demand!

 

cheers

 

Philippe

A Synopsis on Fluid Resus Parameters. #FOAMed, #FOAMcc, #POCUS

Hi, so my good friend Jeff Scott, ED/ICU doc and serious POCUSologist, asked me to summarize our current approach to fluid management, which is an amalgam of literature, physiology and bedside medicine-based evidence.

A few points to emphasize:

  1. does my patient need fluid/ will he/she benefit from fluid.
  2. is my patient fluid tolerant
  3. is my patient fluid responsive – yes, it’s the last and least important

I figure we may follow this up with a discussion – that’s often the best way to get to the real clinical decision points, and it’s always interesting to hear the questions and ideas that come up, so looking forward to it!

I figured might as well make a mini podcast of it, so here it is:

cheers

 

Philippe

“Volume Status” and other meanderings. #FOAMed, #FOAMcc, #FOAMer #POCUS

So the discussions go on about volume status and POCUS, and recently one in particular made me realize that it is important to reframe the way we think about “volume status.” As Segun Olusanya (better known as @iceman_ex) said, “the IVC is not a fuel tank indicator,” and indeed it is not. But even if it was, would that be useful? If somehow, an 18 mm IVC (short axis circular or average of course!) corresponded exactly to a 0.70 ml/kg blood volume, would that be of any use?

No. Of course not.

I get asked this question in consult a lot. So I could be a stickler on principle and answer, whether verbally or in a consult, that the volume status cannot be precisely ascertained using POCUS, and keep walking down the hospital hallway.

But let’s instead reconsider the true clinical question for a moment. What does “volume status” mean when requested by a colleague. The truth is that he or she is likely asking you whether there is a need to give fluid, remove fluid, or stay the course.

Ahhhh. Now POCUS, the IVC and its friends can help. A lot. A lot more that most clinical examinations and chart reviews of weights or ins and outs can. Way more. Why? Because if you are cool, with a normodynamic heart and a small IVC, you are on the low side of volume. Now you may also have a lot of B lines from your pneumonia and the lack of volume tolerance will give your answer to be very careful with fluids. If you are warm and hyperdynamic with a small IVC and totally clear lungs, no elevated ICP and a soft belly, you may just be vasodilated but, if your BP is on the low side, some fluid is a fair go, so long as you follow closely thereafter for fluid stop points. If you have a low urine output, a big IVC, a pulsatile PV and a poor LV, you probably need lasix, no matter how clear your lungs are and even if your creatinine is rising, in fact, especially since it is rising.

The permutations are myriad. But that’s why we have MDs and are supposed to be able to integrate bits and pieces of physiological data to come up with an understanding of our patients. And POCUS gives us an unprecedented bedside view into this physiology.

So if you do have legit POCUS skills, and are able to do a bit more than a long axis M mode of the IVC, then try this instead:

“Sure thing, now tell me a bit about your patient – I imagine you’re debating whether to give some fluids or diurese?”

Forget about volume status in terms of absolutes. Just think of what the clinical question is, and give your colleagues the answers they need.

I think the patients will do a lot better that way.

I’ve already put up a lot of stuff about the IVC here over the years.

cheers

 

Philippe

H&R2019 Lecture Series: GI POCUS with Kylie Baker, #FOAMed, #FOAMus.

Now here is a treat. This is one I am rewatching and taking notes, because it fills some holes in my game. No doubt, my GI POCUS is basic, but now Kylie has me starting to look at layers and patterns.

Anyone in ICU needs to be able to assess the abdomen this way.

So here you go!

 

cheers

 

Philippe

…and for more,

can be found here:

 

H&R2019 The Hospitalist & The Resuscitationist: The Essentials On Demand!

As requested, H&R2019 was recorded, and “The Essentials” is now available on-demand –  CME is currently under processing, so it is currently offered at a temporarily reduced price, until formal accreditation is finalized.

This represents most of the talks originally given in Montreal on May 23rd and 24th, as well as some bonus footage of several workshops as well as some didactic and practical sessions from the pre-congress courses.

Of course, nothing beats being at a conference, especially H&R, whose ethos is not only cutting-edge, but even more so, cutting thru barriers between specialties and between attendees and faculty to take everyone’s game to the next level. But hey, if you couldn’t make it, this is the next best thing.

This second iteration of the coolest conference in Canada brought together a fantastic faculty from all over Canada, the US, Europe and Australia to explore various facets of acute care, from the ED to the wards and the ICU.

Note that this is complimentary for H&R2019 attendees and faculty. If you are, please email hospresusconference@gmail.com to obtain your access code.

         This activity is brought to you by the Cabrini Critical Care Group, and represents 30 key lectures from the annual Hospitalist & Resuscitationist Conference, held at Santa Cabrini Hospital in Montreal, Canada, every spring. Each lecture is approximately 15-20 minutes. There is additional bonus footage from the workshops, the Hospitalist POCUS and Critical Care Procedures courses.

SCIENTIFIC PROGRAMME

Scientific committee:

Dr. Joe Nemeth, MD, CCFP – Emergency Physician

Dr. Carol Zambrana, MD, CCFP – Hospitalist

Dr. Philippe Rola, MD, FRCP – Internal Medicine, Critical Care Physician

Dr. Philippe St-Arnaud, MD, CCFP – Emergency & Critical Care Physician

 

Respiratory failure on the wards – MALLEMAT

At the end of this activity, the participant will be able to recognize and discuss the initial period of respiratory instability using available means including high-flow nasal cannulae and non-invasive positive pressure ventilation.

Phenotyping Cardiac Arrest – SPIEGEL

At the end of this activity, the participant will be able to discuss a new way of approaching cardiac arrest and reframing commonly held beliefs and practices into a more practical and clinical approach.

The Blood Bank and You! AJJAMADA

At the end of this activity, the participant will be able to elaborate the medical management of acute bleeding including the appropriate use of reversal agents and the practical usage of blood products and coagulation factors.

Salvaging the Airway – DUGGAN

At the end of this activity, the participant will be able to approach a respiratory distress caused by an airway problem and explain the different options readily available with their pros and cons.

Advanced POCUS-based management of CHF – ROLA

At the end of this activity, the participant will be able to elaborate on a cutting-edge physiological management of congestive heart failure using bedside ultrasound.

Contrast Induced Nephropathy: 2019 Update – MORRIS

At the end of this activity, the participant will be able to comment on the new literature pertaining to contrast induced nephropathy. The participant will be able to better judge the impact of her/his practice on kidney failure.

A Free Upgrade to your WBC: The NLR! – FARKAS

At the end of this activity, the participant will be able to discuss a different way to look at the white blood cell count which may provide important and overlooked information.

Renal Physiology Demystified: Portal Vein Pulsatility and Hyponatremia – PATEL

At the end of this activity, the participant will be able to integrate venous pressure in renal physiology with practical diagnostic and therapeutic applications.

Life-Threatened Asthmatic – MALLEMAT

At the end of this activity, the participant will be able to recognize the key clinical points of the critically ill asthmatic patient.                                         

The Great EPI debate – SPIEGEL

At the end of this activity, the participant will be able to judge the facts and controversy surrounding the use of epinephrine in cardiac arrest and its impact on survival and neurological outcomes.

Revisiting CPR physiology: What do we know? – TERAN

At the end of this activity, the participant will be able to illustrate the key elements of CPR functioning, including from the standpoint of TEE-obtained intra-arrest data.

pH-guided fluid resuscitation – FARKAS

At the end of this activity, the participant will be able to discuss a tailored-therapy approach to fluid resuscitation and assess the key importance of timing of proper fluids.

Intra-Arrest Hemodynamics: One Size Doesn’t Fit All – TERAN

At the end of this activity, the participant will be able to elaborate on how intra-arrest TEE may help optimize and individualize management of resuscitation.

EKG Pearls – MULLIE

At the end of this activity, the participant will be able to recognize a number of subtle but important “don’t miss” findings in the EKG that can have serious clinical consequences.

Perioperative basics – KAUD

At the end of this activity, the participant will be able to manage the pre- and post-op patient through an organized approach.

Classic Cases with a Twist – SKINNER

At the end of this activity, the participant will be able to identify important and frequent dermatology challenges and will be able to include the concept of skin microbiome to their current practice.

The Art of the Bougie – SPIEGEL

At the end of this activity, the participant will be able to elaborate on the technical pearls, the advantages and the reason to use the bougie in airway management.

Appendicitis Audit from the coal face – BAKER

At the end of this activity, the participant will be able to interpret ultrasound images of appendicitis and recognize the pitfalls in their interpretation.

Diastology for Intensivists – CHEN

At the end of this activity, the participant will be able to elaborate on POCUS diastology and to justify its utility in hemodynamic assessment in the care of the acutely ill patient.

Acid-Base in 3 Parts – SPIEGEL

At the end of this activity, the participant will be able to use a practical and physiological approach to acid-base disorders.

The IVC don’t Lie: Ask the Right Question! – KENNY

At the end of this activity, the participant will be able to oppose the physiology of the IVC to its surroundings and reframe many of the common cognitive pitfalls and common clinical approaches.

Blood Pressure: a Closer Look – MAGDER

At the end of this activity, the participant will be able to define the mechanisms behind the generation of blood pressure and the clinical caveats that are key for resuscitationists to understand.

Gut POCUS – BAKER

At the end of this activity, the participant will be able to identify the findings in GI POCUS and comment on the evidence behind it.

Renal Doppler – HAYCOCK

At the end of this activity, the participant will understand the principles and hemodynamics behind doppler interrogation of renal vasculature and how this may be implemented in clinical practice.

Massive Transfusion – WEIMERSHEIMER

At the end of this activity, the participant will be able to discuss the evolution of massive transfusion protocols, and be able to justify the most recent approach.

To REBOA or Not To REBOA – HAYCOCK

At the end of this activity, the participant will be able to assess the indications for the use of the REBOA device in haemorrhage control and identify the complications associated with it.

Traumatic Cardiac Arrest: How To Avoid Killing the Dead! – NEMETH

At the end of this activity, the participant will be able to oppose the critical differences between medical and traumatic arrest and will recognize the pitfalls of managing the latter.

Inhalation Therapy for acute RV Failure – DENAULT

At the end of this activity, the participant will be able to discuss the advanced therapeutics of right sided failure in the critically ill patients and identify the techniques to diagnose and monitor RV dysfunction.

Pmsa: Is There a Clinical Use? – OLUSANYA

At the end of this activity, the participant will be able to discuss the concept of Pmsa and recognize situations where it can have a direct impact.

Insights on Delirium Using POCUS – DENAULT

At the end of this activity, the participant will be able to comment on the POCUS in relation to the development of delirium.

 

BONUS WORKSHOP & COURSE VIDEOS – this bonus section brings you into some of the workshops of H&R2019, and while watching is no substitute for hands-on practice, these clips are packed with clinical pearls only seasoned veterans can share, and make for a great review prior to doing these procedures as well as teaching them to colleagues and trainees. Due to the organic nature of the workshops, we were not always able to catch the very beginning of each discussion, so we do apologize if you feel like you’re just “jumping in,” but it’s better than missing out! In certain workshops, the audio quality is imperfect due to hearing other groups as well, but again we felt there is valuable learning nonetheless. These reasons are why this is a bonus section.

Lung Ultrasound – OLUSANYA & SPIEGEL

Renal Doppler  – HAYCOCK

Micropuncture kits and Midline Catheters  – SPIEGEL

REBOA – HAYCOCK

Art of the Bougie – SPIEGEL

Hepatic and Portal Venous Doppler – DENAULT

Trans-Cranial Doppler – CHEN & SCOTT

 

…and the bonus section may keep growing as we work on cleaning up audio as much as possible.

 

Please click here for more information and to purchase H&R2019 On Demand:

 

 

And don’t forget to join us next year: